Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 14, 2021 - Issue
Submit an article Journal homepage
90
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Pemphigus Herpetiformis-Type Drug Reaction Caused by Programmed Cell Death Protein-1 Inhibitor Treatment

Yunfang Zhang1 Department of Oncology, Hainan Provincial Hospital of TCM, Haikou, 570203, People’s Republic of ChinaView further author information
,
Ming Zhang2 Department of Dermatology, The Fifth People’s Hospital of Hainan Province, Branch of National Clinical Research Center for Skin and Immune Disease, Haikou, 570206, People’s Republic of ChinaView further author information
,
Jianping Xie2 Department of Dermatology, The Fifth People’s Hospital of Hainan Province, Branch of National Clinical Research Center for Skin and Immune Disease, Haikou, 570206, People’s Republic of ChinaView further author information
,
Weiwei Wu2 Department of Dermatology, The Fifth People’s Hospital of Hainan Province, Branch of National Clinical Research Center for Skin and Immune Disease, Haikou, 570206, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-5029-6936View further author information
ORCID Icon &
Jiejie Lu2 Department of Dermatology, The Fifth People’s Hospital of Hainan Province, Branch of National Clinical Research Center for Skin and Immune Disease, Haikou, 570206, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 1125-1129 | Published online: 27 Aug 2021

References

  • Han Y, Wang J, Xu B. Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103376. doi:10.1016/j.critrevonc.2021.103376
  • Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383–389. doi:10.1158/2326-6066.CIR-15-0123
  • Costa LMC, Cappel MA, Keeling JH. Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria. Int J Dermatol. 2019;58(9):997–1007. doi:10.1111/ijd.14395
  • Yoshimura K, Ishii N, Hamada T, et al. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University. Br J Dermatol. 2014;171(3):544–553. doi:10.1111/bjd.12925
  • Akoglu G, Yavuz SO. Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child. Cutan Ocul Toxicol. 2017;36(3):302–304. doi:10.1080/15569527.2016.1254650
  • Svoboda SA, Huang S, Liu X, et al. Paraneoplastic pemphigus: revised diagnostic criteria based on literature analysis. J Cutan Pathol. 2021:1–6.doi: 10.1111/cup.14004
  • Haydock MM, Sigdel S, Pacioles T. Gemcitabine-induced skin necrosis. SAGE Open Med Case Rep. 2018;6:2050313X18809268. doi:10.1177/2050313X18809268
  • Krammer S, Krammer C, Salzer S, et al. Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy. Front Med. 2019;6:262. doi:10.3389/fmed.2019.00262
  • Yatim A, Bohelay G, Grootenboer-Mignot S, et al. Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Front Med. 2019;6:249. doi:10.3389/fmed.2019.00249
  • BeiGene. Tislelizumab; China prescribing information [Chinese]; 2019. Available from: http://drugs.medlive.cn/drugref/html/21697.shtml. Accessed March, 10 2020.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.